In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Reuben Kapur and Robert Campbell on their latest articles published in Blood. This episode highlights two groundbreaking studies exploring how inflammation drives serious blood and immune-related diseases. In the first interview, Dr. Kapur discusses how inflammatory bowel disease (IBD) can both promote and worsen clonal hematopoiesis of indeterminate potential (CHIP), with large-scale human data and mouse models identifying REF1 as a key mediator and potential therapeutic target. The second segment features Dr. Campbell, who explains how heme released during malaria infection activates platelet mTOR signaling, intensifying cerebral malaria and suggesting new avenues for platelet-targeted treatments. Together, the conversations reveal how inflammatory pathways and immune signaling contribute to disease progression while opening the door to novel precision therapies.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Alexis Thompson, former ASH president, on her latest article published in Blood. Dr. Thompson discusses "Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia." She explains transfusion-dependent β-thalassemia (TDT) requires rigorous, lifelong transfusion therapy and iron chelation to manage iron overload. Dr. Kwiatkowski and colleagues discuss the long-term efficacy and safety of this gene therapy in 63 patients with TDT, documenting sustained transfusion independence for up to 10 years and a safety profile consistent with that of myeloablative autologous transplantation.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Francesco Forconi and Bin Guo on their latest articles published in Blood. Dr. Guo shares insights from "Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming". The findings establish biomechanical regulation as an important determinant of stem cell identity and reveal new strategies for engineering stem cells with enhanced regenerative capacity. Then, Dr. Forconi discusses "DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival". Persistent, low-level BCR engagement by DC-SIGN enables FL tissue retention and survival while avoiding the deleterious proapoptotic consequences of stronger, conventional antigen-driven BCR signaling. These findings help explain how FL cells exploit their microenvironmental niche.